Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27298762 | 0.87 | LPL (0.45) | LPLLIPGPRKCIACHECXCR2 | |
| SCHEMBL31128917 | 0.83 | GAA (0.33) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29178976 | 0.81 | ESR2 (0.33) | LPLLIPGF11 | |
| SCHEMBL25891707 | 0.81 | LPL (0.38) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL27298773 | 0.81 | LIPG (0.45) | LIPGCXCR2F11KMT2A | |
| SCHEMBL21358544 | 0.81 | LPL (0.35) | LPLLIPGCXCR2 | |
| SCHEMBL13202158 | 0.80 | CXCR2 (0.47) | LPLLIPGCA1CA2CXCR2 | |
| SCHEMBL31111473 | 0.80 | HSD17B3 (0.37) | LPLLIPGCXCR2F11UCHL1 | |
| SCHEMBL15450937 | 0.80 | LIPG (0.40) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL28919694 | 0.79 | CASP1 (0.39) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473296-B2 | Perk inhibiting compounds | HIBERCELL, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12331054-B2 | Perk inhibiting imidazolopyrazine compounds | HIBERCELL, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220348583-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | HIBERCELL, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220332722-A1 | PERK INHIBITING COMPOUNDS | HIBERCELL, INC. | 2022-10-20 | — | — | US | disclosed |
| WO-2021041973-A1 | PERK INHIBITING COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041975-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041970-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332722-A1 | PERK INHIBITING COMPOUNDS | ATF4, EEF2K, ERN1 | LPL 1254/4885LIPG 1229/4885PRKCI 122/4885 |
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | EEF2K, ATF4, MAPKAPK2 | LPL 1845/4885LIPG 1709/4885PRKCI 198/4885 |
| US-20220348583-A1 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | MAPKAPK2, MAPK4, MAP3K5 | LPL 2155/4885LIPG 2300/4885PRKCI 190/4885 |
| US-12331054-B2 | Perk inhibiting imidazolopyrazine compounds | MAPKAPK2, MAPK4, MAP3K5 | LPL 2155/4885LIPG 2300/4885PRKCI 190/4885 |
| US-12473296-B2 | Perk inhibiting compounds | MAPK1, ERN1, MAP3K20 | LPL 794/4885LIPG 1043/4885PRKCI 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.